Raising the CD4+ initiation threshold with our eyes wide open

South African Medical Journal

Volumn 103, Issue 11, 2013, Pages 834-

  Venter, W D F ^a   Barker, P M ^b,c  

^a UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^b INSTITUTE FOR HEALTHCARE IMPROVEMENT   (United States)

^c UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

Antiretroviral therapy initiation threshold; Antiretrovirals; CD4 count

Indexed keywords

CD4 ANTIGEN; STAVUDINE;

CD4 LYMPHOCYTE COUNT; DISEASE TRANSMISSION; EDITORIAL; HEALTH CARE SYSTEM; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; LIFE EXPECTANCY; PRACTICE GUIDELINE; TUBERCULOSIS;

EID: 84886020279     PISSN: 02569574     EISSN: None     Source Type: Journal    
DOI: 10.7196/SAMJ.7462     Document Type: Editorial

References (11)

1. World Health Organization. Consolidated Guidelines on the Use of Antiretroviral Drugs for Treating and Preventing HIV Infection. Geneva: WHO, 2013. http://www.who.int/hiv/pub/guidelines/arv2013/download/en/index.html (accessed 20 August 2013).
2. Johnson L, Mossong J, Dorrington R, et al. Life expectancies of HIV-positive adults receiving antiretroviral treatment in South Africa. Presented at the Actuarial Society of South Africa (ASSA) 2012 Convention, Cape Town, South Africa, 16-17 October 2012. http://www.africanagenda.com/convention2012registration/assets/pdf/papers/Leigh%20Johnson%20-%20LIFE%20EXPECTANCIES%20OF%20HIV-POSITIVE%20ADULTS.pdf (accessed 23 September 2013).
3. Pillay Y. Treatment 2013-current issues and future directions. Presented at the 7th IAS Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2013), Kuala Lumpur, Malaysia, 30 June-3 July 2013. http://pag.ias2013.org/session.aspx?s=63 (accessed 20 August 2013).
4. Tanser F, Bärnighausen T, Grapsa E, Zaidi J, Newell ML. High coverage of ART associated with decline in risk of HIV acquisition in rural KwaZulu-Natal, South Africa. Science 2013;339(6122):966-971. [http://dx.doi.org/10.1126/science.1228160]
5. Fisher M, Cooper V. HIV and ageing: Premature ageing or premature conclusions? Curr Opin Infect Dis 2012;25(1):1-3. [http://dx.doi.org/10.1097/QCO.0b013e32834f14fa]
6. Sabin CA, Ryom L, De Wit S, et al. Associations between immune depression and cardiovascular events in HIV infection. AIDS 2013; Aug 6, Epub. [http://dx.doi.org/10.1097/01.aids.0000432457.91228.f3]
7. Bateman C. Drug stock-outs: Inept supply-chain management and corruption. S Afr Med J 2013;103(9):600-602. [http://dx.doi.org/10.7196/SAMJ.7332]
8. Southern African HIV Clinicians Society. Statement on WHO consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection, 15 August 2013. http://www.sahivsoc.org/upload/documents/SA%20HIV%20Clinicians%20Society%20Statement%20on%20WHO%202013%20Guidelines.pdf (accessed 31 August 2013).
9. Fauci AS, Pantaleo G, Stanley S, Weissman D. Immunopathogenic mechanisms of HIV infection. Ann Intern Med 1996;124(7):654-663. [http://dx.doi.org/10.7326/0003-4819-124-7-199604010-00006]
10. Johnson LF. Access to antiretroviral treatment in South Africa, 2004-2011. Southern African Journal of HIV Medicine 2012;13(1):22-27.
11. Barron P, Pillay Y, Doherty T, et al. Eliminating mother-to-child HIV transmission in South Africa. Bull World Health Organ 2013;91(1):70-74. [http://dx.doi.org/10.2471/BLT.12.10680]